

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI APPTEC CO., LTD.\***  
**無錫藥明康德新藥開發股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2359)**

**VOLUNTARY ANNOUNCEMENT**

**UPDATES ON BUSINESS STATUS**

This announcement is made by WuXi AppTec Co., Ltd.\* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) on a voluntary basis to provide its shareholders and investors with updates on its business status.

**I. GENERAL**

As of the date of this announcement, the Company has resumed its regular business operations in Shanghai. During April 2022 and May 2022, the Company continued to strengthen its unique integrated Contract Research Development and Manufacturing Organization (CRDMO) and Contract Testing Development and Manufacturing Organization (CTDMO) business models. While adhering to COVID-19 pandemic prevention and control measures in Shanghai, the Company also swiftly formulated and effectively implemented its business continuity plan, fully capitalizing on its global capacity, multiple operational locations and comprehensive coverage across industry supply chains, which ensured the achievement of the Company’s overall performance targets. The Company reiterates that its second quarter revenue will grow 63% to 65% year over year as earlier disclosed, and the Company remains confident that its full year revenue will grow 65% to 70% year over year for 2022.

## II. EXPLANATORY MATTERS

The aforementioned operating performance forecast for the second quarter of 2022 and the full year of 2022 is based on the current order backlog of the Company. It has not been audited and does not constitute a profit forecast for the second quarter of 2022 or the full year of 2022, nor is it a substantive undertaking by the Company to its investors. In addition, such operating performance forecasts are subject to various prerequisites, including the stabilization or improvement of the COVID-19 global pandemic, the stable development of the global pharmaceutical industry and the stability of the international trade and regulatory environment of the countries where the Company operates. Consequently, the realization of the operating performance forecast is uncertain and subject to multiple factors, including changes in the internal and external environment. The Company will closely monitor subsequent developments in the prevention and control of the COVID-19 pandemic in Shanghai, and will make timely disclosures in relation to its impact on the Company's business development.

**Shareholders of the Company and investors should pay attention to the investment risks involved, and exercise caution when dealing in the securities of the Company.**

By order of the Board  
**WuXi AppTec Co., Ltd.\***  
**Dr. Ge Li**  
*Chairman*

Hong Kong, June 5, 2022

*As of the date of this announcement, the board of directors of the Company comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Dr. Minzhang Chen, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive directors and Dr. Jiangnan Cai, Ms. Yan Liu, Dr. Hetong Lou, Mr. Xiaotong Zhang and Mr. Dai Feng, as independent non-executive directors.*

\* *For identification purposes only*